Recurrent Adrenocortical Carcinoma Completed Phase 1 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0028855 (Recurrent Adrenocortical Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004074Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuTreatment